Home Stock

Stock Research: Sumitomo Dainippon Pharma

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Sumitomo Dainippon Pharma

TYO:4506 JP3495000006
94
  • Value
    98
  • Growth
    84
  • Safety
    Safety
    45
  • Combined
    92
  • Sentiment
    86
  • 360° View
    360° View
    94
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Sumitomo Pharma Co Ltd is a pharmaceutical company. It operates in the pharmaceutical industry and regenerative medicine. The company operates in Japan, North America, and Asia. In the last fiscal year, the company had a market cap of $2729 million, profits of $1637 million, revenue of $2660 million, and 3832 employees.

more

ANALYSIS: With an Obermatt 360° View of 94 (better than 94% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Sumitomo Dainippon Pharma are very positive. The 360° View is based on consolidating four consolidated indicators, with all but one indicator above average for Sumitomo Dainippon Pharma. The consolidated Value Rank has an attractive rank of 98, which means that the share price of Sumitomo Dainippon Pharma is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means the stock price is lower than for 98% of alternative stocks in the same industry. The consolidated Growth Rank has a good rank of 84, which means that the company experiences above-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth, as well as stock returns. In addition, professional market sentiment is above average compared with other stock investment alternatives with a Sentiment Rank of 86. But the company’s financing is risky with a Safety rank of 45. This means 55% of comparable companies have a safer financing structure than Sumitomo Dainippon Pharma. ...read more

more
Strongest Rank Refinancing
Weakest Rank Price vs. Earnings (P/E)
Country Japan
Industry Pharmaceuticals
Size Large
Website sumitomo-pharma.co.jp
Index
Nikkei 225
Sumitomo Dainippon Pharma stock price by TradingView. Not sourced by Obermatt.
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 10-Aug-2026.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Value
Identifies how good a value the stock is.
Good Value Expensive
Combined
Consolidated view across Value, Growth, and Safety.
Good Tread Carefully
Growth
Shows a company's growth potential.
High Growth Tough Times
Sentiment
Shows what the market thinks of a stock.
Positive Sentiment Skepticism
Safety
Safety
Assesses how financially secure a company is.
Well-Financed High Leverage
360° View
360° View
Holistic stock analysis: all key non-/financial metrics
Good Watch Out

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 30 66 97
Growth
84 88 21 7
Safety
Safety
45 1 1 49
Sentiment
86 14 1 1
360° View
360° View
94 10 4 19
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Analyst Opinions
29 1 1 9
Opinions Change
91 82 31 50
Pro Holdings
n/a 26 1 47
Market Pulse
95 5 3 10
Sentiment
86 14 1 1
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Value
98 30 66 97
Growth
84 88 21 7
Safety Safety
45 1 1 49
Combined
92 18 10 47
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Price vs. Sales (P/S)
77 91 100 95
Price vs. Earnings (P/E)
100 33 97 93
Price vs. Book (P/B)
76 31 97 89
Dividend Yield
71 1 1 68
Value
98 30 66 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Revenue Growth
89 22 76 9
Profit Growth
54 86 21 30
Capital Growth
57 76 51 8
Stock Returns
60 98 1 57
Growth
84 88 21 7
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2025 2024 2023
Leverage
46 1 5 22
Refinancing
18 1 1 77
Liquidity
82 7 10 51
Safety Safety
45 1 1 49

Similar Stocks

Discover high‑ranked alternatives to Sumitomo Dainippon Pharma and broaden your portfolio horizons.

Mitsubishi Materials

TYO:5711
Country: Japan
Industry: Diversified Metals & Mining
Size: X-Large
Full Stock Analysis

Kohnan Shoji

TYO:7516
Country: Japan
Industry: Home Improvement Retail
Size: Large
Full Stock Analysis

Kansai Electric Power

TYO:9503
Country: Japan
Industry: Electric Utilities
Size: Large
Full Stock Analysis

Megmilk Snow Brand

TYO:2270
Country: Japan
Industry: Packaged Foods & Meats
Size: Large
Full Stock Analysis

Frequently Asked
Questions

This is a high-quality, high-growth stock with positive sentiment. However, the financing is on the riskier side. It is best for a growth-focused investor willing to accept higher financial risk for potentially higher shareholder returns.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

OTHER FEATURES

Use the Platform to its Fullest

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing:

Review us See More Google Reviews